Navin Fluorine International Ltd Q4 FY2026 Concall Summary

Key Takeaways

• Six quarters of growth, margin surge: Revenue and profitability rose for a sixth straight quarter, with FY26 EBITDA margins expanding 992 bps to 32.6%, driven by operating leverage and pricing actions.
• CDMO leads the charge: The CDMO segment grew revenue 61% YoY in Q4, powered by a balanced mix of early, late-stage and commercial molecules, putting the \$100 mn FY27 revenue target within reach.
• AHF and Chemours milestones hit: The AHF plant was commissioned and began commercial supplies, while the Chemours project remains on track for a June/July completion, anchoring the next leg of HPP growth.
• Employee cost optimization complete: A one-time optimization phase held employee cost growth to just 4% YoY; going forward, normal increases of 7.5%–9% will resume, so the margin tailwind from this lever is now exhausted.
• What to watch next quarter: The pace of Chemours ramp-up, any Middle East shipment upside, and whether the CDMO mix shift pressures gross margins further.

CDMO: The Growth Engine

• Broad-based molecule execution: Q4 revenue jumped 61% YoY, reflecting strong delivery across oncology, respiratory, cardiovascular, neurology and animal health. The pipeline spans early, late-stage and commercial molecules, with 13 new molecules added in FY26 and three in Q4 alone.
• Revenue target in sight: FY26 revenue of INR541 crores puts the business on a solid trajectory toward the stated \$100 mn target by FY27. Management is pushing hard for that number.
• cGMP4 now live: The dedicated Fermion block (cGMP4) was commissioned in December and revenue is kicking in this year. Manufacturing currently done elsewhere will move into it, freeing capacity and improving efficiency.
• Fermion Phase 2 optionality: Space exists for cGMP5, 6 and 7, and the business is scalable if the case materializes. Management declined to disclose Fermion's FY26 contribution or pricing revision triggers, citing commercial sensitivity.
• Mix shift is a margin wildcard: Gross margins held stable at ~58% sequentially despite the CDMO ramp, but margin expansion depends on both inter-business and intra-business mix. The addition of 13 new molecules in FY26, including three in Q4, will influence that mix going forward.

Ganatra: "we've always maintained that we will endeavor to do 30%. Given what we know today of the business circumstances, plus/minus 1% to 2%, which we've always said, yes."

HPP: Capacity Coming, Demand Constructive

• AHF plant commissioned: The AHF plant was successfully commissioned and commercial supplies commenced during Q4, adding a new revenue stream and strengthening backward integration.
• Chemours project on track: Completion is expected by end June/early July. Navin Fluorine is the sole manufacturing site for Chemours on this product, which is essential to support AI-driven growth. Initial capacities will seed market adoption; over the next 18 months, a better understanding of market size will determine further capex.
• R32 expansion underway: Additional HFC capacity equivalent to 15,000 metric tons per annum of R32 is on track for commissioning in Q3 FY27. The business benefits from a constructive global demand-supply environment, increasing adoption of low GWP refrigerants, and export opportunities.
• Honeywell capacity headroom: Room exists to expand within the same capacity by another 20% whenever demand materializes, offering low-capex upside.
• Q4 sequential dip explained: The Q3-to-Q4 decline stemmed from a planned shutdown and an opportunistic catalyst recharge ahead of the heat season to maximize Q1 value, plus the absence of Middle East shipments worth INR15–16 crores. Management is working on Q1 numbers excluding Middle East; any movement there will be upside.
• Sales shift toward India: As the business scales from INR250–300 crores to INR400 crores per quarter, the customer base is changing. New R32 contracts in India and new geographies/export customers are driving a marked shift in sales toward the domestic market.

Ganatra: "70% of that for Navin is coming from our capacities coming on the ground, our volumes going up and 30% is coming from affirmative actions on pricing that we've taken."

Specialty Chemicals: Agrochemical Visibility, Nectar Ramp

• Strong Q4 execution: Revenue grew 39% YoY, reflecting strong delivery in both existing and new molecules. Scale-up in ongoing products is supported by customer confidence and long-term contracts.
• FY27 visibility solid: Visibility extends to roughly 80% of capacity utilization for FY27, underpinned by the 13 new molecules completed in FY26. Management expects price rises to be flattish as the year progresses, with volume increases doing the heavy lifting.
• Nectar project de-risked: An additional molecule from the client improves risk management. Shipments outside contracted revenues for qualification are under progress, and downstream applications are being worked on. Utilization is targeted at 50%–60% this year, rising to 70%–75% in the coming year.
• Nectar utilization tempered: Management would have liked full utilization by end of FY28 (two years), but is now realistically targeting 75%–80% by that date. The ramp is progressing, just more gradually than initially hoped.

Ganatra: "we would have liked to have a full utilization by end of FY28, which would be the 2 years. But I think we are realistically talking about 75% to 80% is where we will get to by end of FY28."

Margins: The 30% Endeavor

• FY26 margin walk: EBITDA margins expanded 992 bps to 32.6% for the full year. Per management's math, 70% of the EBITDA growth came from capacities coming on ground and volumes rising, while 30% came from affirmative pricing actions.
• Employee cost lever spent: Employee benefit expenses rose only 4% YoY despite scale-up, reflecting a one-time optimization phase that is now complete. Going forward, normal increases in the 7.5%–9% range will resume, removing a key margin tailwind.
• Currency and inflation a wash: The currency tailwind and raw material inflation largely offset each other. Net EBITDA growth was driven by operating leverage meeting capacity, not external factors. Management is confident it can pass on price increases to finished products and sees no material raw material risk currently.
• FY27 margin guidance: Management will endeavor to deliver 30% EBITDA margins for the full year, plus/minus 1%–2%, based on current business circumstances. Gross margins held stable at ~58% sequentially, but the CDMO mix shift remains a variable to watch.

Capex & Capacity: The Growth Backbone

• Dahej MPP debottlenecking: Capex is progressing well, with commissioning targeted for Q3 FY27. This will unlock additional capacity across the portfolio.
• HF plant commissioned: The HF plant was commissioned in February; revenues will begin flowing in FY28, adding a new block to the growth stack.
• Chemours further capex: Premature to quantify today, but management says it is fair to assume it should be reasonable given the product's unique benefits and AI-driven growth. The decision will follow 18 months of market observation after initial capacities are placed.
• Working capital discipline: Net working capital days improved to 74 from 90, and the new guidance range is 75–80 days, down from the previous 90. Contract liabilities increased, reflecting customer capital contributions toward the Chemours project and a marquee project for additional molecules.

Risk & Resilience

• Geopolitical monitoring: Management is closely tracking geopolitical developments, particularly their implications for energy prices, logistics and supply chain disruptions. Post-geopolitical situation, further restocking demand may emerge; currently, no demand destruction is visible.
• Oil price scenario not priced in: At \$150 sustained oil prices, management acknowledges a concern that global demand may slow, but it is not seeing that today and is not planning on that scenario. The focus is on ensuring resilience.
• R22 quota clarity sought but not given: An analyst asked whether only the company's R22 quota would be eligible for redistribution on a pro rata basis under Kigali rules. Management discussed the right to win from quota but did not directly confirm or deny the specific regulatory clarity sought.

Ganatra: "at \$150 sustained oil prices, I think there is a concern that the global demand may slow. But today, we are not seeing that. We can't factor that. What we are doing today is making sure that we are resilient."

Guidance & Commitments

Key Metrics